Form D · Pharmaceuticals

Reiley Pharmaceuticals, Inc.

San Francisco, CA · CIK 0001616308

Offering snapshot reported Jun 5, 2024 · SEC filing

Reported sold
$97.7K
Offering amount: $247K
Investors reported
6
Form D · investor count
Minimum accepted
$2.5K
Reported outside-investor minimum
First sale
May 31, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 5, 2024Initial$97,655No comparison6SEC filing
Oct 19, 2022Amendment$100,000$0vs Oct 18, 20222SEC filing
Oct 18, 2022Initial$100,000No comparison2SEC filing
Aug 3, 2020Initial$1,052,868No comparison27SEC filing
Oct 24, 2019InitialYet to sellNo comparison0SEC filing
Nov 7, 2017Initial$1,200,000No comparison19SEC filing
Jan 6, 2016Initial$1,100,000No comparison20SEC filing
Aug 29, 2014Initial$980,000No comparison15SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-515144

Source: Form D, filed Jun 5, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeff Dunn Director
Jeffrey Dunn Director
Donald Kiepert Director, Executive
Mark Reiley Promoter
B Michael Silber Executive
B. Michael Silber Director
Keith Valentine Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3749 Buchanan Street Suite 475745
San Francisco, CA, 94147